tenofovir + emtricitabine

Phase 2Small molecule

SSt Stephens Aids Trust

tenofovir + emtricitabine is one of 71 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

EncephalopathyActive, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

EncephalopathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 4

Incivek

Vertex Pharmaceuticals

Preclinical

10 5

Intron a

Sanofi

Preclinical

7 6

Roferon-a

Roche

Preclinical

3 7

Medrol

Pfizer

Preclinical

1 8

Dasabuvir

AbbVie

Preclinical

7 9

tenofovir + emtricitabine

SSt Stephens Aids Trust

Phase 2

1 10

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tics1 trial

Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid

Unknown status·SSt Stephens Aids Trust·Phase 1·NCT02832778·35 enrolled

Pre-Exposure Prophylaxis (PrEP)1 trial

PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.

Recruiting·DDesmond Tutu HIV Foundation··NCT06807736·1,800 enrolled

Chronic Hepatitis1 trial

Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B

Terminated·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00524173·35 enrolled

Pregnancy1 trial

SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women

Completed·SSt Stephens Aids Trust·Phase 1·NCT02499874·26 enrolled

Single Dose1 trial

Single Dose Truvada in HIV-negative Men and Women

Completed·UUniversity of North Carolina, Chapel Hill··NCT01326221·12 enrolled

2 more indications

Encephalopathy1 trial

Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00120367·30 enrolled

Bone Health1 trial

Bone Health in Aging HIV Infected Women

Completed·UUniversity Health Network, Toronto·Phase 4·NCT02815566·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for tenofovir + emtricitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tenofovir + emtricitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tenofovir + emtricitabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St Stephens Aids Trust company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSt Stephens Aids Trust

tenofovir + emtricitabine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tics1 trial

Pre-Exposure Prophylaxis (PrEP)1 trial

Chronic Hepatitis1 trial

Pregnancy1 trial

Single Dose1 trial

Encephalopathy1 trial

Bone Health1 trial

References

Drug Info

Quick Facts

Related News